Burnham already uses evidence-based PRP (platelet-rich plasma) and other biologic treatments where clinical evidence supports them
10.1016/S2215-0366(18)30269-4 15 DanielsonM
Peptides Module III Peptides Module IV 7:30 am Peptide Overview and Cancer Treatments William Seeds, MD 8:00 am Cancer Nutrition and Labs James LaValle, RPh 9:30 am Break 10:00 am Peptides Target Cell Cycle Andrew Heyman MD 11:00 am Tumor Targeting Peptides Andrew Heyman MD 12:00 pm Lunch 1:30 pm Cell Penetrating Peptides Tumor Targeting Peptides William Seeds, MD 3:30 pm Break 4:00 pm Peptides Target Tumor Suppressor Protein Peptide Target Transcription Factors Nima Alavi 6:00 pm Close of Session 7:30 am Anti-Aging Protocols: Final Assumptions William Seeds, MD 8:30 am Laboratory Initial Evaluation and Follow Up James LaValle, RPh 9:30 am Break 10:00 am Peptides in the future, Breakthroughs in Peptide Understanding James LaValle, RPh 11:00 am Nutrition and Supplement Protocol James LaValle, RPh 12:00 pm Lunch 1:30 pm Type I and Type II Ground Breaking Origin William Seeds, MD 3:30 pm Break 4:00 pm Peptide Treatment for Acute and Chronic Infections Kent Holtorf, MD 6:00 pm Close of Session 7:30 am Nutrients for Type 2 Diabetes James LaValle, RPh 9:30 am Break 10:00 am Peptides in Treatment of Chronic Fatigue Syndrome William Seeds, MD 12:00 pm Lunch - Sponsored by Legally Mine 1:30 pm Rheumatoid Arthritis, SLE, Psoriasis and PA, Ankylosing Spondylitis William Seeds, MD 3:30 pm Break 4:00 pm Nutrition and Supplements for RA, SLE, PA, AS James LaValle, RPh 5:00 pm Case Studies: Infections and Metabolic Disease William Seeds, MD James LaValle, RPh Kent Holtorf, MD Andrew Heyman, MD Kathy O'Neil-Smith, MD 6:00 pm Close of Session 7:30 am Inflammatory Bowel Disease, Chrons Disease, Ulcerative Colitis Kathy O'Neil-Smith, MD, FAARM 8:30 am Nutrition and Supplements for GI Tract James LaValle, RPh 9:30 am Break 10:00 am Neuroinflammation Andrew Heyman, MD 11:00 am Dementia & Autism William Seeds, MD 12:00 pm Lunch 1:30 pm Amyotrophic Lateral Sclerosis, Multiple Sclerosis Kathy O'Neil-Smith, MD 2:30 pm Alzheimers, Parkinson Kathy O'Neil-Smith, MD 3:30 pm Break 4:00 pm Nutrition and Supplements: Neuronal Disease James LaValle, RPh 5:00 pm Case Studies: Peptides and Neuronal Disease Kathy O'Neil-Smith, MD, FAARM William Seeds, MD James LaValle, RPh Andrew Heyman, MD 6:00 pm Close of Session 3355 Las Vegas Blvd
In some embodiments, the formulations or compositions are substantially free of microorganisms
It is an investigational compound presented here for research and educational purposes only and is not approved for general human use
Met carriers produce less activity-dependent BDNF and may show poorer episodic memory performance and steeper age-related cognitive decline
